Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Date:5/2/2013

therapy in men with metastatic CRPC, and ENSPIRIT will evaluate the potential survival benefit of combining custirsen with docetaxel as second-line chemotherapy in patients with advanced or metastatic NSCLC.

"The initiation of multiple investigator-sponsored Phase 2 trials, across tumor types, represents a significant inflection point in the creation of value for OGX-427 for which we currently retain all commercialization rights," said Scott Cormack , President and Chief Executive Officer, OncoGenex Pharmaceuticals, Inc. "Considered alongside the three Phase 3 trials of custirsen, and a strong cash position that will sustain us into 2015, well past the SYNERGY data read-out, we believe the company is well situated to continue to execute against our development goals."

First Quarter 2013 Financial Update and Results

  • Revenue for the first quarter of 2013 increased to $5.1 million from $1.3 million for the first quarter of 2012. The increase was due to higher revenue earned through the Company's strategic collaboration with Teva, resulting from clinical development activities associated with the AFFINITY trial which was initiated in August 2012.
  • Total operating expenses for the first quarter of 2013 increased to $13.4 million from $6.8 million for the first quarter of 2012. The increase was due primarily to higher clinical trial expenses associated with patient enrollment in the AFFINITY and Borealis-1 trials, increased costs directly associated with efforts to increase patient enrollment and higher employee expenses, including stock based compensation expenses.  These increases were partially offset by lower manufacturing expenses due to timing of OGX-427 manufacturing activities.
  • Net loss for the first quarter of 2013 was $6.7 million, or $0.46 per diluted common share compared with a net loss of $6.9 million, or $0.67 per diluted common share for the first quarter of 2012.  The
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    3. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    4. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
    6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
    7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
    8. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
    9. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
    10. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
    11. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
    (Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
    (Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
    Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
    ...  Swedish Covenant Hospital today announced the success of its ... Guided Surgery by Brainlab, the ultimate command and control ... option to use image guidance for a prone, occipital ... visualization in these types of procedures, and makes me ...
    ... a leading Contract Research Organization (CRO) and services provider for ... has been appointed Chief Medical Officer. In this role, Dr. ... management related to genae,s research services. "I am ... will be of great benefit to the many aspects of ...
    Cached Medicine Technology:Curve Image Guided Surgery Provides Swedish Covenant Hospital With a State-of-the-Art Command and Control Center for Information-Guided Surgery 2Curve Image Guided Surgery Provides Swedish Covenant Hospital With a State-of-the-Art Command and Control Center for Information-Guided Surgery 3genae Appoints Chief Medical Officer 2
    (Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
    (Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
    (Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
    (Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
    (Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
    Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2
    ... probability of tumor response ... and accelerates drug development, SEATTLE, Oct. ... Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, today announced ... trial of brostallicin used in combination,with either bevacizumab or irinotecan, ...
    ... results include 19 percent sales growth and EPS of $.85, Q3 pro forma adjusted results ... ... EPS guidance updated to $3.50 - $3.55, or ... $2.76 - $2.81 reported, INDIANAPOLIS, Oct. 18 Eli Lilly and Company,(NYSE: LLY ) ...
    ... Consecutive Quarter, DEERFIELD, Ill., Oct. 18 Baxter ... results for the period,ended September 30, 2007 and raised ... quarter net income of $395 million increased 6 percent ... 2006. Net earnings per,diluted share of $0.61 increased 7 ...
    ... Blood Pressure Cuff and Weight Scale Added to Our ... Telemedicine Product ... Sheets: XMDC) announced the company has added two new,Bluetooth(R) enabled telemedicine ... care, hospitals, long term care,facilities, and physician groups. "The addition ...
    ... More than half of holiday shoppers (57,percent) plan ... good cause*. This,year, choose a gift that will brighten ... the seventh leading cause of death,in the United States. ... families struggling with,Alzheimer,s or support innovative research grants, which ...
    ... Inc. (NASDAQ:QLTI;,TSX:QLT) today reported that Novartis AG announced ... million for the quarter ended,September 30, 2007. This ... the,third quarter of 2006 and a 17.9% decline ... in the U.S. for the quarter were approximately ...
    Cached Medicine News:Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 2Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 3Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 4Health News:Lilly Delivers Strong Third-Quarter Results 2Health News:Lilly Delivers Strong Third-Quarter Results 3Health News:Lilly Delivers Strong Third-Quarter Results 4Health News:Lilly Delivers Strong Third-Quarter Results 5Health News:Lilly Delivers Strong Third-Quarter Results 6Health News:Lilly Delivers Strong Third-Quarter Results 7Health News:Lilly Delivers Strong Third-Quarter Results 8Health News:Lilly Delivers Strong Third-Quarter Results 9Health News:Lilly Delivers Strong Third-Quarter Results 10Health News:Lilly Delivers Strong Third-Quarter Results 11Health News:Lilly Delivers Strong Third-Quarter Results 12Health News:Lilly Delivers Strong Third-Quarter Results 13Health News:Lilly Delivers Strong Third-Quarter Results 14Health News:Lilly Delivers Strong Third-Quarter Results 15Health News:Lilly Delivers Strong Third-Quarter Results 16Health News:Lilly Delivers Strong Third-Quarter Results 17Health News:Lilly Delivers Strong Third-Quarter Results 18Health News:Lilly Delivers Strong Third-Quarter Results 19Health News:Baxter Reports Strong Third Quarter Sales and Earnings 2Health News:Baxter Reports Strong Third Quarter Sales and Earnings 3Health News:Baxter Reports Strong Third Quarter Sales and Earnings 4Health News:Baxter Reports Strong Third Quarter Sales and Earnings 5Health News:Baxter Reports Strong Third Quarter Sales and Earnings 6Health News:Baxter Reports Strong Third Quarter Sales and Earnings 7Health News:Baxter Reports Strong Third Quarter Sales and Earnings 8Health News:Baxter Reports Strong Third Quarter Sales and Earnings 9Health News:Baxter Reports Strong Third Quarter Sales and Earnings 10Health News:Baxter Reports Strong Third Quarter Sales and Earnings 11Health News:Baxter Reports Strong Third Quarter Sales and Earnings 12Health News:Baxter Reports Strong Third Quarter Sales and Earnings 13Health News:Baxter Reports Strong Third Quarter Sales and Earnings 14Health News:Baxter Reports Strong Third Quarter Sales and Earnings 15
    Supplied sterile in peel-open packages. Intended for one-time use....
    Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
    Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use....
    Used under fluoroscopy for initial location and positioning of the renal collecting system throughout a percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
    Medicine Products: